Evidence map›Paper›PMID 34642671›Full record

ArticleSTAR protocols2021

Domain-specific biochemical and serological characterization of SARS-CoV-2 nucleocapsid protein.

Chao Wu, Abraham J Qavi, Austin B Moyle, Nicole D Wagner, Asmaa Hachim, Niloufar Kavian, Aidan R Cole, Joyce Sweeney-Gibbons, Henry W Rohrs, J S Malik Peiris and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in STAR protocols, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Chao WuDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
Abraham J QaviDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
Austin B MoyleDepartment of Chemistry, Washington University in St. Louis, St. Louis, MO 63110, USA.
Nicole D WagnerDepartment of Chemistry, Washington University in St. Louis, St. Louis, MO 63110, USA.
Asmaa HachimHKU-Pasteur Research Pole, School of Public Health, The University of Hong Kong, Hong Kong, China.
Niloufar KavianHKU-Pasteur Research Pole, School of Public Health, The University of Hong Kong, Hong Kong, China.
Aidan R ColeDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
Joyce Sweeney-GibbonsCenter for Microbial Pathogenesis, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
Henry W RohrsDepartment of Chemistry, Washington University in St. Louis, St. Louis, MO 63110, USA.
J S Malik PeirisHKU-Pasteur Research Pole, School of Public Health, The University of Hong Kong, Hong Kong, China.
Christopher F BaslerCenter for Microbial Pathogenesis, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
Michael L GrossDepartment of Chemistry, Washington University in St. Louis, St. Louis, MO 63110, USA.
Sophie A ValkenburgHKU-Pasteur Research Pole, School of Public Health, The University of Hong Kong, Hong Kong, China.
Christopher W FarnsworthDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
Gaya K AmarasingheDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
Daisy W LeungDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
Washington University in St. Louis · USHKU-Pasteur Research Pole · HKGeorgia State University · USDélégation Paris 5 · FR

Funding

Virology BSL4 CoreP01AI120943 · NIAID · WASHINGTON UNIVERSITY · PI Gaya K. Amarasinghe · 2016 to 2026
$30.2M
TRAINING IN THE IMMUNOBIOLOGY AND MOLECULAR CELL BIOLOGY OF CANCERT32CA009547 · NCI · WASHINGTON UNIVERSITY · PI ROBERT DAVID SCHREIBER · 1986 to 2026
$12.1M
TrainingP41GM103422 · NIGMS · WASHINGTON UNIVERSITY · PI YARASHESKI, KEVIN E · 2012 to 2019
$12.0M
Novel VP30-host Interactions that Negatively Regulate Ebola Virus InfectionR01AI143292 · NIAID · WASHINGTON UNIVERSITY · PI AMARASINGHE, GAYA K., BASLER, CHRISTOPHER F · 2019 to 2023
$4.0M
Intersection Between Viral Translation and Innate Immunity in the Context of Filovirus InfectionR01AI148663 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BASLER, CHRISTOPHER F · 2020 to 2024
$3.0M
A Biomedical Mass Spectrometry Resource: Ongoing Driving Biomedical ProjectsR24GM136766 · NIGMS · WASHINGTON UNIVERSITY · PI GROSS, MICHAEL L · 2020 to 2022
$2.3M
Multi-platform High Throughput Screens for Filoviral Replication InhibitorsR01AI123926 · NIAID · WASHINGTON UNIVERSITY · PI AMARASINGHE, GAYA K. · 2016 to 2018
$2.1M
STRUCTURAL BASIS FOR IMMUNE EVASION BY RSV NON-STRUCTURAL PROTEINSR01AI107056 · NIAID · WASHINGTON UNIVERSITY · PI LEUNG, DAISY W · 2013 to 2017
$1.9M
Integrated Platform for Mass-Spectrometric Studies of Protein StructureR42GM121133 · NIGMS · PROTEIN METRICS, LLC · PI BERN, MARSHALL WAYNE · 2020 to 2021
$1.2M
NCI NIH HHS T32 CA009547NIAID NIH HHS HHSN272201400006CNIAID NIH HHS P01 AI120943NIAID NIH HHS R01 AI107056NIAID NIH HHS R01 AI123926NIAID NIH HHS R01 AI143292NIAID NIH HHS R01 AI148663NIGMS NIH HHS P41 GM103422NIGMS NIH HHS R24 GM136766NIGMS NIH HHS R42 GM121133
6 · The paper itself

Abstract

Nucleocapsid proteins are essential for SARS-CoV-2 life cycle. Here, we describe protocols to gather domain-specific insights about essential properties of nucleocapsids. These assays include dynamic light scattering to characterize oligomerization, fluorescence polarization to quantify RNA binding, hydrogen-deuterium exchange mass spectrometry to map RNA binding regions, negative-stain electron microscopy to visualize oligomeric species, interferon reporter assay to evaluate interferon signaling modulation, and a serology assay to reveal insights for improved sensitivity and specificity. These assays are broadly applicable to RNA-encapsidated nucleocapsids. For complete details on the use and execution of this protocol, please refer to Wu et al. (2021).

Indexed as

Antiviral AgentsCoronavirus Nucleocapsid ProteinsCOVID-19HumansInterferonsNucleocapsidPhosphoproteinsProtein BindingRNA, ViralSARS-CoV-2Antiviral AgentsCoronavirus Nucleocapsid ProteinsInterferonsnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsRNA, ViralBiophysicsClinical ProtocolHealth SciencesImmunologyMass SpectrometryMicrobiologyMicroscopyMolecular BiologyProtein BiochemistryProtein expression and purificationStructural Biology

Identifiers

PMID34642671
PMCPMC8495048
OpenAlexW3205824462

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.